Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amgen

338.45
+14.794.57%
Pre-market: 338.00-0.4500-0.13%07:04 EST
Volume:3.14M
Turnover:1.05B
Market Cap:182.25B
PE:26.17
High:338.55
Open:323.42
Low:323.42
Close:323.66
52wk High:338.55
52wk Low:253.30
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.90
T/O Rate:0.58%
Dividend:9.39
Dividend Rate:2.77%
EPS(TTM):12.93
EPS(LYR):7.62
ROE:81.71%
ROA:7.71%
PB:18.95
PE(LYR):44.44

Loading ...

Government Shutdown Nears End, Lifting Investors' Spirits -- and Stocks -- WSJ

Dow Jones
·
15 hours ago

Amgen Inc. Stock Rises 4.6%, Outperforms Market

Dow Jones
·
15 hours ago

US STOCKS-Dow notches record high close; traders bet on end to government shutdown

Reuters
·
15 hours ago

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2025-11-11

Reuters
·
17 hours ago

Deutsche Bank Adjusts Amgen Price Target to $285 From $280, Maintains Hold Rating

MT Newswires Live
·
Yesterday

Obesity Drugs Are About to Go Mass-Market -- Heard on the Street -- WSJ

Dow Jones
·
Yesterday

Merck's Heart Pill Slashes Cholesterol Levels in Test Patients -- Barrons.com

Dow Jones
·
Yesterday

PharmaEssentia Appoints Dr. Barry Flannelly as Independent Director

Reuters
·
Nov 10

Amgen's Repatha® Demonstrates Primary Prevention Benefits

Deep News
·
Nov 10

Nurix Therapeutics Appoints Roger Dansey to Board of Directors

Reuters
·
Nov 10

Amgen Says Repatha Significantly Reduces Risk of Cardiovascular Event in Phase 3 Study

MT Newswires Live
·
Nov 10

DZ Bank Adjusts Price Target on Amgen to $364 From $335

MT Newswires Live
·
Nov 10

Amgen announces results from Phase 3 VESALIUS-CV trial

TIPRANKS
·
Nov 10

More Drugs to Fight High Cholesterol Are Emerging -- WSJ

Dow Jones
·
Nov 09

Biotech stocks are coming back. Here's what's driving the sector higher.

Dow Jones
·
Nov 09

BRIEF-Amgen Says Repatha Cuts Risk Of First Major Adverse Cardiovascular Events By 25% In Phase 3 Vesalius-CV Trial

Reuters
·
Nov 08

Amgen: Repatha Cuts Risk of First Major Adverse Cardiovascular Events by 25% in Phase 3 Vesalius-Cv Trial

THOMSON REUTERS
·
Nov 08

Amgen: Study Also Shows 36% Reduction in Risk of Heart Attack

THOMSON REUTERS
·
Nov 08

Amgen cholesterol drug cuts risk of first cardiac event by 25%

Reuters
·
Nov 08

REUTERS NEWS SCHEDULE AT 11:00 am GMT/ 6:00 am ET

Reuters
·
Nov 08